BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hušáková M, Bay-Jensen AC, Forejtová Š, Zegzulková K, Tomčík M, Gregová M, Bubová K, Hořínková J, Gatterová J, Pavelka K, Siebuhr AS. Metabolites of type I, II, III, and IV collagen may serve as markers of disease activity in axial spondyloarthritis. Sci Rep 2019;9:11218. [PMID: 31375691 DOI: 10.1038/s41598-019-47502-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Su G, Li G, Wang W, Xu L. Application Prospect and Preliminary Exploration of GelMA in Corneal Stroma Regeneration. Polymers (Basel) 2022;14:4227. [PMID: 36236174 DOI: 10.3390/polym14194227] [Reference Citation Analysis]
2 Port H, Nielsen SH, Madsen SF, Bay-Jensen AC, Karsdal M, Seven S, Sørensen IJ, Morsel-Carlsen L, Østergaard M, Pedersen SJ. Extracellular matrix protein turnover markers are associated with axial spondyloarthritis-a comparison with postpartum women and other non-axial spondyloarthritis controls with or without back pain. Arthritis Res Ther 2022;24:152. [PMID: 35739562 DOI: 10.1186/s13075-022-02839-1] [Reference Citation Analysis]
3 Holers VM, La Rosa FG, Banda NK. A Potential New Mouse Model of Axial Spondyloarthritis Involving the Complement System. Immune Netw 2021;21:e45. [PMID: 35036032 DOI: 10.4110/in.2021.21.e45] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Reveille JD. Biomarkers in axial spondyloarthritis and low back pain: a comprehensive review. Clin Rheumatol 2021. [PMID: 34674081 DOI: 10.1007/s10067-021-05968-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Belhabib I, Zaghdoudi S, Lac C, Bousquet C, Jean C. Extracellular Matrices and Cancer-Associated Fibroblasts: Targets for Cancer Diagnosis and Therapy? Cancers (Basel) 2021;13:3466. [PMID: 34298680 DOI: 10.3390/cancers13143466] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 15.0] [Reference Citation Analysis]
6 Groen SS, Sinkeviciute D, Bay-Jensen AC, Thudium CS, Karsdal MA, Thomsen SF, Schett G, Nielsen SH. Exploring IL-17 in spondyloarthritis for development of novel treatments and biomarkers. Autoimmun Rev 2021;20:102760. [PMID: 33485992 DOI: 10.1016/j.autrev.2021.102760] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Fager Ferrari M, Zetterberg E, Rossing M, Manon-Jensen T, Pehrsson M, Karsdal MA, Lykkesfeldt J, Leinoe E. Collagen remodelling and plasma ascorbic acid levels in patients suspected of inherited bleeding disorders harbouring germline variants in collagen-related genes. Haemophilia 2021;27:e69-77. [PMID: 33161638 DOI: 10.1111/hae.14195] [Reference Citation Analysis]
8 Lorenzin M, Ometto F, Ortolan A, Felicetti M, Favero M, Doria A, Ramonda R. An update on serum biomarkers to assess axial spondyloarthritis and to guide treatment decision. Ther Adv Musculoskelet Dis 2020;12:1759720X20934277. [PMID: 32636944 DOI: 10.1177/1759720X20934277] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]